ArticleJournal of translational medicine2025
EMP1 + hepatic stellate cells drive hepatic fibrosis progression to hepatocellular carcinoma and predict prognosis.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHepatic fibrosis is a pathological response to chronic liver injury that results in accumulation of extracellular matrix proteins leading to fibrous scarring, which can further lead to hepatocellular carcinoma (HCC). Although several clinical approaches have been applied to the diagnosis and treatment of hepatic fibrosis and HCC, the clinical prognosis and precision of targeted therapies still face great challenges.
methodsIn this study, we integrated multi-omics data to identify functional subpopulations of hepatic stellate cells (HSCs) closely associated with hepatic fibrosis and HCC. Based on this, differential genes derived from single-cell and bulk transcriptomic analyses were used to construct and validate a clinical prognostic model using 101 machine learning algorithms. Furthermore, we explored the expression heterogeneity of core prognostic genes (CPGs) and their correlation with clinical outcomes. A comprehensive network pharmacology analysis was also conducted to identify potential drugs targeting these genes, aiming to discover novel targeted therapeutic strategies.
resultsWe identified a specific functional subpopulation of HSCs, characterized by EMP1 expression (EMP1 + HSCs), and elucidated the cellular functional pathways through which EMP1 + HSCs contribute to the progression from hepatic fibrosis to HCC. Subsequently, we identified and evaluated four CPGs-NPY1R, CTHRC1, IGFBP3, and ADH1B-for their expression heterogeneity and prognostic significance along the fibrosis-to-HCC axis, with biological validation at the proteomic level. Finally, network pharmacology analysis identified Salvia miltiorrhiza (Danshen) as a potential therapeutic agent targeting all four CPGs, offering a new direction for the treatment of hepatic fibrosis and HCC.
conclusionThis study, through the integration of multi-omics data, establishes EMP1 as a reliable marker of activated HSCs. The genes NPY1R, CTHRC1, IGFBP3, and ADH1B play critical regulatory roles and exhibit prognostic value in the progression from hepatic fibrosis to HCC. Our findings provide novel insights and therapeutic targets for the use of Salvia miltiorrhiza in treating hepatic fibrosis and HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.